AstraZeneca Pharma India Ltd reported a 36% revenue increase in Q1 2025-26, reaching INR 5263.1 million, thanks to growth in oncology and strategic execution. The results highlight the company's commitment to innovation and expanding its portfolio amidst ongoing regulatory milestones.